Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action

  • Cerro-Herreros, E.
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Naldaiz-Gastesi, N.
  • Carrascosa-Sàez, M.
  • García-Rey, A.
  • Losilla, D.P.
  • González-Martínez, I.
  • Espinosa-Espinosa, J.
  • Moreno, K.
  • Poyatos-García, J.
  • Vilchez, J.J.
  • López de Munain, A.
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
  • Llamusí, B.
  • Artero, R.
This study evaluated therapeutic antimiRs in primary myoblasts from patients with myotonic dystrophy type 1 (DM1). DM1 results from unstable CTG repeat expansions in the DMPK gene, leading to variable clinical manifestations by depleting muscleblind-like splicing regulator protein MBNL1. AntimiRs targeting natural repressors miR-23b and miR-218 boost MBNL1 expression but must be optimized for a better pharmacological profile in humans. In untreated cells, miR-23b and miR-218 were up-regulated, which correlated with CTG repeat size, supporting that active MBNL1 protein repression synergizes with the sequestration by CUG expansions in DMPK. AntimiR treatment improved RNA toxicity readouts and corrected regulated exon inclusions and myoblast defects such as fusion index and myotube area across CTG expansions. Unexpectedly, the treatment also reduced DMPK transcripts and ribonuclear foci. A leading antimiR reversed 68% of dysregulated genes. This study highlights the potential of antimiRs to treat various DM1 forms across a range of repeat sizes and genetic backgrounds by mitigating MBNL1 sequestration and enhancing protein synthesis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immortalized human myotonic dystrophy type 1 muscle cell lines to address patient heterogeneity

  • Núñez-Manchón, Judith
  • Capó, Júlia
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Juanola, Eduard
  • Pesovic, Jovan
  • Mosqueira-Martín, Laura
  • González-Imaz, Klaudia
  • Maestre-Mora, P.
  • Odria, Renato|||0000-0002-3420-797X
  • Savic-Pavicevic, Dusanka
  • Vallejo-Illarramendi, Ainara
  • Mamchaoui, Kamel
  • Bigot, Anne|||0000-0003-0337-5425
  • Mouly, Vicent
  • Suelves, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Historically, cellular models have been used as a tool to study myotonic dystrophy type 1 (DM1) and the validation of therapies in said pathology. However, there is a need for in vitro models that represent the clinical heterogeneity observed in patients with DM1 that is lacking in classical models. In this study, we immortalized three DM1 muscle lines derived from patients with different DM1 subtypes and clinical backgrounds and characterized them at the genetic, epigenetic, and molecular levels. All three cell lines display DM1 hallmarks, such as the accumulation of RNA foci, MBNL1 sequestration, splicing alterations, and reduced fusion. In addition, alterations in early myogenic markers, myotube diameter and CTCF1 DNA methylation were also found in DM1 cells. Notably, the new lines show a high level of heterogeneity in both the size of the CTG expansion and the aforementioned molecular alterations. Importantly, these immortalized cells also responded to previously tested therapeutics. Altogether, our results show that these three human DM1 cellular models are suitable to study the pathophysiological heterogeneity of DM1 and to test future therapeutic options.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

HDAC11 deficiency regulates age-related muscle decline and sarcopenia

  • Odria, Renato
  • Cardús, Aina
  • Gomis-Coloma, Clara
  • Balanyà-Segura, Marta
  • Mercado-Amarilla, Alexandra
  • Maestre-Mora, Pau
  • Poveda-Sabuco, Andrea
  • Domingo, Joan Carles
  • Nogales-Gadea, Gisela
  • Gómez-Sánchez, José A.
  • Hurtado, Erica
  • Suelves, Mònica
Sarcopenia, defined as the progressive loss of skeletal muscle mass and function associated with ageing, has devastating effects in terms of reducing the quality of life of older people. Muscle ageing is characterised by muscle atrophy and decreased capacity for muscle repair, including a reduction in the muscle stem cell pool that impedes recovery after injury. Histone deacetylase 11 (HDAC11) is the newest member of the HDAC family and it is highly expressed in skeletal muscle. Our group recently showed that genetic deficiency in HDAC11 increases skeletal muscle regeneration, mitochondrial function and globally improves muscle performance in young mice. Here, we explore for the first time the functional consequences of HDAC11 deficiency in old mice, in homeostasis and during muscle regeneration. Aged mice lacking HDAC11 show attenuated muscle atrophy and postsynaptic fragmentation of the neuromuscular junction, but no significant differences in the number or diameter of myelinated axons of peripheral nerves. Maintenance of the muscle stem cell reservoir and advanced skeletal muscle regeneration after injury are also observed. HDAC11 depletion enhances mitochondrial fatty acid oxidation and attenuates age-associated alterations in skeletal muscle fatty acid composition, reducing drastically the omega-6/omega-3 fatty acid ratio and improving significantly the omega-3 index, providing an explanation for improved muscle strength and fatigue resistance and decreased mortality. Taken together, our results point to HDAC11 as a new target for the treatment of sarcopenia. Importantly, selective HDAC11 inhibitors have recently been developed that could offer a new therapeutic approach to slow the ageing process., Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was supported by Ministerio de Economía y Competitividad (BFU2016-80748 to M.S.), Ministerio de Ciencia, Innovación y Universidades (PID2020-118730RB-I00 to M.S. and PID2022-143269OB-I00 to J.A.G-S.), Instituto de Salud Carlos III (PI22/00104 to G.N-G.) and Feder funds. R.O. was supported in part by AFM 23557 project; A.M-A. was supported by the BECAL National Programme of Scholarships Abroad Don Carlos Antonio López; P.M-M. was supported by the Programa Investigo 2022 INV-1 00008 (Generalitat de Catalunya); J.A.G-S. and G.N-G. were supported by a Miguel Servet Fellowship from the Instituto de Salud Carlos III (CP22/00078 and CPII19/00021, respectively) and E.H. was partially supported by BFU2016-80748., Peer reviewed